Cleaner Blood Tests A Device That Diverts Contaminating Skin Bacteria Before They Reach the Sample

A US medical device company has patented an ingenious fluid diversion system that captures and isolates the first portion of a blood draw before it reaches the sample collection vessel – dramatically reducing the risk of false-positive results caused by skin bacteria that hitch a ride on the needle during venepuncture. The invention has major implications for accurate diagnosis of bloodstream infections and the appropriate use of antibiotics.

The Problem

When a healthcare worker draws blood for microbial testing, the needle must pass through the patient’s skin. The skin surface harbours harmless bacteria – a normal part of the human microbiome – and even with careful disinfection, some of these microbes can be introduced into the blood sample on the needle tip during the puncture. This contamination, known as a “false positive” blood culture, is a persistent and costly problem in clinical medicine.

A false positive blood culture – where bacteria are detected not because they are in the patient’s bloodstream but because they contaminated the sample – leads to unnecessary antibiotic prescriptions, extended hospital stays, additional testing and significant patient anxiety. Studies suggest that blood culture contamination rates range from 1 to 3 per cent in routine practice, but the downstream costs in wasted treatment and misdiagnosis are enormous.

Healthcare settings have long sought a reliable mechanical way to divert or discard that first flush of blood – the portion most likely to carry surface contaminants – before routing subsequent clean blood to the collection vessel. Previous solutions have been cumbersome, unreliable or difficult to integrate into standard clinical workflows.

What This Invention Does

Magnolia Medical Technologies‘ invention addresses this problem with an elegant single-device solution. The apparatus consists of a housing with an inlet port (connected to the patient via a needle) and an outlet port (connected to standard sample collection bottles). Inside the housing sits a fluid reservoir designed to capture and isolate the first small volume of blood drawn – the portion most contaminated with skin microbes.

A flow control mechanism, rotatable between two configurations, governs where the blood flows. In the first configuration, blood flows from the inlet directly into the fluid reservoir, filling it with that potentially contaminated first volume. Once the reservoir is full, an actuator rotates the flow control mechanism to the second configuration, routing all subsequent blood flow from the inlet to the outlet port – and on to the clean sample collection vessels.

The actuator also creates the negative pressure (suction) needed to draw blood into the reservoir in the first place, and then automatically switches the flow path once the required volume has been collected. The result is a seamless, single-device process that diverts contaminating skin bacteria before they can reach the diagnostic sample, without requiring additional steps from the clinician.

Key Features

Automatic first-volume diversion. The device captures and isolates the first flush of blood – the most likely to carry skin contaminants – before any fluid reaches the sample collection vessel, without requiring manual intervention by the clinician.

Rotating flow control mechanism. A precision rotatable mechanism with two distinct flow configurations ensures a clean, positive transition between diversion mode and collection mode, eliminating the risk of mixing contaminated and clean blood.

Integrated negative pressure actuator. The actuator both draws blood into the diversion reservoir and triggers the switch to collection mode once the reservoir is full, creating an automatic and reliable sequence of operation.

Single-device workflow. The entire diversion and collection process is managed within one compact device, integrating with standard blood culture collection bottles and existing clinical workflows with minimal disruption.

Broad contamination scope. By targeting all dermal microbes – not just specific bacterial species – the device provides protection against a wide range of potential contaminants, including bacteria, fungi and yeasts.

Who Is Behind It?

Magnolia Medical Technologies, Inc. is a Seattle-based medical device company specialising in blood culture contamination reduction. This application is a divisional of AU 2024203105 and traces its origins to a US provisional application filed in May 2012, with a full US application filed in May 2013 – reflecting many years of development and clinical validation. The inventors are Jay Miazga, Richard G. Patton, Gregory J. Bullington and Shan E. Gaw. The Australian application is managed by Pizzeys Patent and Trade Mark Attorneys Pty Ltd in Canberra.

Why It Matters

Blood culture contamination is one of those problems in healthcare that is easy to overlook but carries a disproportionately large cost. Unnecessary antibiotic prescriptions driven by false positive cultures contribute directly to the global crisis of antimicrobial resistance – one of the most pressing threats in modern medicine. Every contaminated sample that triggers an unnecessary course of antibiotics is a small but real contribution to a growing problem that threatens to undermine the effectiveness of treatments that the entire world depends on.

Beyond antimicrobial stewardship, the clinical and financial costs of managing contaminated blood cultures – repeated testing, extended stays, specialist consultations – are substantial. A device that can meaningfully reduce contamination rates in clinical practice would deliver measurable benefits across hospital systems worldwide. With IPC classifications spanning blood sampling (A61B 5/15), fluid separation (B01D 43/00) and microbiological analysis (G01N 33/49), the invention sits at the crossroads of diagnostics, infection control and patient safety.

---

AU 2026201507 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.

Related Concepts

Blood culture contamination is a well-documented source of diagnostic error, with false-positive results driving unnecessary antibiotic use that worsens the global threat of antimicrobial resistance. The initial portion of blood collected during venipuncture carries the greatest contamination risk because it may contain skin-plug bacteria dislodged by the needle, making diversion of this first volume a clinically sound strategy for improving diagnostic accuracy.